AB46273
Packsize | Purity | Availability | Price | Discounted Price | Quantity | |
---|---|---|---|---|---|---|
1mg | in stock | $10.00 | $7.00 | - + | ||
5mg | in stock | $23.00 | $17.00 | - + | ||
10mg | in stock | $34.00 | $24.00 | - + | ||
100mg | in stock | $50.00 | $35.00 | - + | ||
250mg | in stock | $101.00 | $71.00 | - + | ||
1g | in stock | $298.00 | $209.00 | - + | ||
5g | in stock | $1,179.00 | $825.00 | - + | ||
10g | in stock | $1,879.00 | $1,316.00 | - + |
*All products are for research use only and not intended for human or animal use.
*All prices are in USD.
Catalog Number: | AB46273 |
Chemical Name: | (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (Synonyms:Ruxolitinib) |
CAS Number: | 941678-49-5 |
Molecular Formula: | C17H18N6 |
Molecular Weight: | 306.3650 |
MDL Number: | MFCD12031592 |
SMILES: | N#CC[C@@H](n1ncc(c1)c1[nH]cnc2c1ccn2)C1CCCC1 |
Complexity: | 453 |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 1 |
Heavy Atom Count: | 23 |
Hydrogen Bond Acceptor Count: | 4 |
Hydrogen Bond Donor Count: | 1 |
Rotatable Bond Count: | 4 |
XLogP3: | 2.1 |
(βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile is a highly versatile compound commonly used in chemical synthesis as a key building block for the creation of various pharmaceuticals, agrochemicals, and materials. Its unique molecular structure allows it to participate in a wide range of reactions, making it an essential tool for organic chemists.In chemical synthesis, this compound serves as a valuable intermediate for the preparation of diverse bioactive molecules due to its functional groups and stereochemistry. Its cyclopentyl and pyrazole moieties provide opportunities for further derivatization, enabling the introduction of specific substituents to tailor the properties of the final products. Additionally, the pyrrolopyrimidine core confers biological activity, making this compound particularly useful in the design and development of new drugs.Overall, (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile plays a crucial role in the strategic construction of complex molecules, showcasing its importance in modern organic synthesis and drug discovery efforts.
The Lancet. Haematology 20180201
Archives of toxicology 20170101
European journal of pharmacology 20151015
Nature cell biology 20150101
Journal of medicinal chemistry 20141009
Chemico-biological interactions 20140905
Nature medicine 20140901
Toxicology 20140801
Journal of medicinal chemistry 20140626
Antimicrobial agents and chemotherapy 20140401
Journal of immunology research 20140101
Bioorganic & medicinal chemistry letters 20130801
Expert opinion on pharmacotherapy 20130501
Arthritis and rheumatism 20121201
Journal of medicinal chemistry 20121126
Drugs 20121112
Expert opinion on pharmacotherapy 20121101
Blood 20121025
Journal of the American Academy of Dermatology 20121001
Hematology/oncology clinics of North America 20121001
Molecular diagnosis & therapy 20121001
Cancer control : journal of the Moffitt Cancer Center 20121001
Deutsche medizinische Wochenschrift (1946) 20121001
Blood 20120927
Journal of immunology (Baltimore, Md. : 1950) 20120915
Blood 20120816
Blood 20120809
Blood 20120712
Leukemia 20120701
Journal of medicinal chemistry 20120628
Clinical cancer research : an official journal of the American Association for Cancer Research 20120615
Journal of clinical pharmacology 20120601
Clinical cancer research : an official journal of the American Association for Cancer Research 20120601
Blood 20120517
The Medical letter on drugs and therapeutics 20120402
Leukemia 20120401
Hematology (Amsterdam, Netherlands) 20120401
Hematology (Amsterdam, Netherlands) 20120401
Blood 20120322
Current opinion in hematology 20120301
Current hematologic malignancy reports 20120301
The New England journal of medicine 20120301
The New England journal of medicine 20120301
Nature reviews. Drug discovery 20120201
Clinical advances in hematology & oncology : H&O 20120201
Nature biotechnology 20120109
PloS one 20120101
Mayo Clinic proceedings 20111201
Drugs of today (Barcelona, Spain : 1998) 20111101
Nature biotechnology 20111030
The New England journal of medicine 20111013
Future oncology (London, England) 20110901
Expert opinion on investigational drugs 20110801
Current opinion in hematology 20110301
Leukemia 20110201
The New England journal of medicine 20101216
Bioorganic & medicinal chemistry letters 20101215
Chemistry & biology 20101124
Drug metabolism and disposition: the biological fate of chemicals 20101101
IDrugs : the investigational drugs journal 20100601
Blood 20100415
Organic letters 20090507
Current opinion in hematology 20090301
Hematology. American Society of Hematology. Education Program 20090101